Blog
    Regulatory UpdateFor PhysiciansMay 12, 2026

    Peptide FDA regulatory status and FAERS safety signals

    Review FDA 503A Category 2 restrictions for BPC-157 and TB-500, plus emerging FAERS signals for semaglutide including NAION and pulmonary aspiration risks.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    How do current FDA regulatory designations, warning letters, and post-marketing safety signals influence the clinical evaluation of peptide therapies, specifically regarding compounding eligibility and emerging adverse event profiles?

    Evidence Snapshot

    • Regulatory Designations: Numerous peptides (BPC-157, TB-500, Ipamorelin) classified as Category 2 bulk substances as of September 2023.
    • FDA Status: Multiple peptides used in clinical research remain non-FDA approved, with some nominations withdrawn as of September 2024 (e.g., AOD-9604, CJC-1295).
    • Safety Signals: Strong signals for gastrointestinal events (nausea, vomiting, delayed gastric emptying) and emerging signals for NAION and pulmonary aspiration identified in FAERS for semaglutide.
    • Clinical Outcomes: Evidence varies from significant weight loss in semaglutide Phase III trials (14.9%) to negative mortality outcomes in Thymosin Alpha-1 sepsis studies.

    What the Research Shows

    Regulatory and Compounding Status As of March 2026, the FDA has significantly restricted the use of several bulk peptide substances in compounding. BPC-157, TB-500, and GHK-Cu are currently listed under 503A Category 2, indicating they are considered to pose significant safety risks and are ineligible for routine compounding. Peptides such as AOD-9604, CJC-1295, Selank, and Ipamorelin had their nominations withdrawn and were removed from eligibility in September 2024.

    FDA warning letters have been issued to multiple entities, including Tailor Made Compounding (2020) and Predator Nutrition (October 2020), concerning the distribution or production of these substances. While Thymosin Alpha-1 is approved in over 35 countries as Zadaxin, it remains non-FDA approved in the United States and continues to be categorized as a substance of concern under interim policy.

    Safety Signal Analysis (FAERS) Safety data for semaglutide reveals a complex adverse event profile. Strong signals exist for gastrointestinal distress, including nausea, vomiting, and delayed gastric emptying. The latter has led to clinical concerns regarding oral medication absorption and pre-surgical risks. Recently, pulmonary aspiration was added to the Ozempic label in 2025 due to risks occurring during general anesthesia.

    More severe gastrointestinal signals include moderate signals for acute pancreatitis and cholelithiasis/cholecystitis. Intestinal obstruction and ileus are noted as emerging signals added to labeling post-marketing. Regarding non-gastrointestinal systems, acute kidney injury signals have been detected, often secondary to GI-related dehydration. Of particular note is the emerging signal for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, leading to a formal EMA review in January 2025.

    Clinical Trial Outcomes Clinical data for approved and investigational agents show high efficacy in weight management but mixed results in other indications. The semaglutide STEP 1 trial (NCT03548935) demonstrated 14.9% weight loss, while the SELECT trial (NCT03574597) showed a 20% MACE reduction. Tirzepatide (NCT04184622) demonstrated 22.5% weight loss, and retatrutide Phase II data (NCT04881706) showed 24.2% weight loss at 12mg. Conversely, a Phase III trial for Thymosin Alpha-1 in sepsis (NCT02867267) was negative, showing no reduction in mortality.

    Mechanism

    No specific chemical mechanism data was provided for clinical review in the source records for the listed regulatory statuses or safety signals beyond the mention of immunogenicity risks for BPC-157, TB-500, GHK-Cu, and GHRP-2. The clinical action for semaglutide's pulmonary aspiration risk is attributed to the peptide's contribution to delayed gastric emptying.

    Limitations of the Evidence

    Several significant gaps exist in the current literature. For peptides like TB-500, the FDA cites a total lack of human exposure data. BPC-157 evidence is currently limited by immunogenicity concerns and a general lack of safety data. For many substances currently in Category 2, the primary data leading to their restriction are safety risks identified by regulatory bodies rather than published human clinical trials. Furthermore, the signal for suicidal ideation with semaglutide remains under evaluation, as current data do not support a higher risk compared to background rates.

    Clinical Takeaway

    The regulatory landscape for peptides is characterized by increasing FDA oversight, with many formerly compounded substances now restricted due to safety and immunogenicity concerns. For approved GLP-1 receptor agonists, safety monitoring must extend beyond common gastrointestinal effects to include emerging risks such as NAION and perioperative pulmonary aspiration.

    Sources

    • Regulatory Status Records: 0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b
    • FAERS Safety Signals: 502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa
    • Clinical Trial Records: 65446b68, 2f6b401e, 91163f2f, c4da06d8, 1b33afa2, 733e7bb7, 081507ec, 55115d78, 61da059a

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1tb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.